Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)

Psyence Biomedical (NASDAQ:PBM) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings & Valuation

This table compares Psyence Biomedical and XBiotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01 million	$25.34	0.10
XBiotech	N/A	N/A	-$45.54 million	($1.50)	-1.50

XBiotech is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Psyence Biomedical and XBiotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1	0	0	0	1.00
XBiotech	1	0	0	0	1.00

Profitability

This table compares Psyence Biomedical and XBiotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
XBiotech	N/A	-27.80%	-26.67%

Insider and Institutional Ownership

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Psyence Biomedical has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Summary

Psyence Biomedical beats XBiotech on 6 of the 8 factors compared between the two stocks.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.